MX2023004834A - Formulaciones de vacunas de glicoconjugados de expec. - Google Patents

Formulaciones de vacunas de glicoconjugados de expec.

Info

Publication number
MX2023004834A
MX2023004834A MX2023004834A MX2023004834A MX2023004834A MX 2023004834 A MX2023004834 A MX 2023004834A MX 2023004834 A MX2023004834 A MX 2023004834A MX 2023004834 A MX2023004834 A MX 2023004834A MX 2023004834 A MX2023004834 A MX 2023004834A
Authority
MX
Mexico
Prior art keywords
vaccine formulations
expec
glycoconjugate vaccine
expec glycoconjugate
coli
Prior art date
Application number
MX2023004834A
Other languages
English (en)
Inventor
Janik Adriaansen
Olga Labovitiadi
Wouter Frank Tonnis
Francesco Doro
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2023004834A publication Critical patent/MX2023004834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones y métodos para inducir una respuesta inmunitaria contra Escherichia coli patógena extraintestinal (ExPEC). En particular, se describen vacunas multivalentes que contienen un polisacárido que es un antígeno de E. coli unido covalentemente a una proteína portadora que es una exotoxina A de Pseudomonas aeruginosa (EPA) que pueden soportar múltiples estreses medioambientales.
MX2023004834A 2016-10-24 2019-04-22 Formulaciones de vacunas de glicoconjugados de expec. MX2023004834A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16195256 2016-10-24

Publications (1)

Publication Number Publication Date
MX2023004834A true MX2023004834A (es) 2023-05-10

Family

ID=57206056

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019004689A MX2019004689A (es) 2016-10-24 2017-10-24 Formulaciones de vacunas de glicoconjugados de expec.
MX2023004834A MX2023004834A (es) 2016-10-24 2019-04-22 Formulaciones de vacunas de glicoconjugados de expec.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019004689A MX2019004689A (es) 2016-10-24 2017-10-24 Formulaciones de vacunas de glicoconjugados de expec.

Country Status (25)

Country Link
US (5) US10159751B2 (es)
EP (1) EP3528839B1 (es)
JP (1) JP6698220B2 (es)
KR (1) KR102576346B1 (es)
CN (1) CN109996559A (es)
AR (1) AR109621A1 (es)
AU (1) AU2017349163B2 (es)
BR (1) BR112019007803A2 (es)
CA (1) CA3038705A1 (es)
CL (1) CL2019001104A1 (es)
CO (1) CO2019003949A2 (es)
EA (1) EA201991033A1 (es)
ES (1) ES2966895T3 (es)
HR (1) HRP20240171T1 (es)
HU (1) HUE065328T2 (es)
IL (1) IL266080B (es)
MA (1) MA46661B1 (es)
MX (2) MX2019004689A (es)
MY (1) MY191842A (es)
PH (1) PH12019500561A1 (es)
PL (1) PL3528839T3 (es)
RS (1) RS65125B1 (es)
SG (1) SG11201902567WA (es)
TW (1) TWI734853B (es)
WO (1) WO2018077853A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014111516A1 (en) 2013-01-17 2014-07-24 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AR118389A1 (es) 2019-03-18 2021-09-29 Janssen Pharmaceuticals Inc Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
IL301248B2 (en) 2020-09-17 2024-04-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and their uses
CN117098550A (zh) 2021-04-08 2023-11-21 杨森制药公司 生物缀合物生产方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
FI102976B (fi) 1994-02-28 1999-03-31 Valtion Teknillinen Menetelmä lisäkeittokemikaalien tuottamiseksi sekä käyttämiseksi sulfa attiselluloosaprosessissa
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
EP1278548A2 (en) 2000-04-18 2003-01-29 Endobiologics, Incorporated Lipopolysaccharide-conjugate vaccine for sepsis treatment
RU2189253C1 (ru) 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20050287628A1 (en) 2002-03-07 2005-12-29 Markus Aebi System and method for the production of recombinant glycosylated proteins in a prokaryotic host
EP1517698B2 (en) * 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
EP1638523B8 (en) * 2003-06-30 2013-12-25 ALZA Corporation Formulations for coated microprojections containing non-volatile counterions
EP2289911A3 (en) 2004-03-30 2011-03-30 NsGene A/S Therapeutic use of a growth factor, NsG33
WO2005117948A1 (en) * 2004-06-01 2005-12-15 Ares Trading S.A. Method of stabilizing proteins
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
AU2006245969B8 (en) 2005-05-11 2011-08-25 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
JP4791866B2 (ja) 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
US8895014B2 (en) 2008-02-20 2014-11-25 Glycovaxyn Ag Bioconjugates made from recombinant N-glycosylated proteins from procaryotic cells
EA024697B1 (ru) 2009-04-27 2016-10-31 Иммурон Лимитед Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени
EP2475393A4 (en) * 2009-09-14 2013-08-21 Vu Truong-Le FORMULATION FOR THE ROOM TEMPERATURE STABILIZATION OF A WEAKED LIVING BACTERIAL VACCINE
AU2010322454B2 (en) 2009-11-19 2016-05-19 Glaxosmithkline Biologicals S.A. Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
BR112013005049A2 (pt) * 2010-09-02 2016-05-31 Sanofi Pasteur estabilizador para a preparação de uma composição vacina da pólio seca injetável
CA2819366A1 (en) 2010-12-10 2012-06-14 Merck Sharp & Dohme Corp. Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions
MX352604B (es) * 2011-05-13 2017-11-30 Zoetis Llc Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
AU2012306345A1 (en) 2011-09-06 2014-03-20 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
WO2013038385A2 (en) * 2011-09-14 2013-03-21 Novartis Ag Escherichia coli vaccine combination
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
AU2013311534A1 (en) 2012-09-10 2015-03-12 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
EA201590488A1 (ru) 2012-10-12 2015-09-30 Гликоваксин Аг Способы модификации клеток-хозяев
WO2014102265A1 (en) 2012-12-27 2014-07-03 Glycovaxyn Ag Methods and compositions relating to crm197
WO2014111516A1 (en) 2013-01-17 2014-07-24 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP2968535A2 (en) * 2013-03-15 2016-01-20 Glaxosmithkline Intellectual Property (No. 2) Limited Low concentration antibody formulations
ES2778074T3 (es) 2013-10-11 2020-08-07 Glaxosmithkline Biologicals Sa Procedimientos de modificación de células hospedadoras
PL3096785T3 (pl) * 2014-01-21 2021-03-08 Pfizer Inc. Kompozycje immunogenne zawierające skoniugowane antygeny sacharydów otoczkowych i ich zastosowania
EP3102599B1 (en) 2014-02-06 2019-02-27 ARSANIS Biosciences GmbH E. coli specific antibody sequences
LT3110441T (lt) 2014-02-24 2024-04-25 Glaxosmithkline Biologicals S.A. Naujas polisacharidas ir jo panaudojimas
PT3240895T (pt) 2014-12-30 2022-03-02 Glaxosmithkline Biologicals Sa Composições e métodos para glicosilação de proteínas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
AR118389A1 (es) 2019-03-18 2021-09-29 Janssen Pharmaceuticals Inc Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof

Also Published As

Publication number Publication date
WO2018077853A1 (en) 2018-05-03
MY191842A (en) 2022-07-18
SG11201902567WA (en) 2019-05-30
AU2017349163B2 (en) 2019-10-31
US20210275681A1 (en) 2021-09-09
IL266080B (en) 2022-05-01
JP2019535678A (ja) 2019-12-12
EA201991033A1 (ru) 2019-09-30
MX2019004689A (es) 2019-11-18
PH12019500561A1 (en) 2019-11-25
MA46661B1 (fr) 2024-02-29
HUE065328T2 (hu) 2024-05-28
IL266080A (en) 2019-06-30
CO2019003949A2 (es) 2019-07-31
AR109621A1 (es) 2018-12-26
US20190105402A1 (en) 2019-04-11
AU2017349163A1 (en) 2019-04-11
MA46661A (fr) 2019-08-28
EP3528839C0 (en) 2023-11-08
US20180110870A1 (en) 2018-04-26
PL3528839T3 (pl) 2024-03-25
US20200101167A1 (en) 2020-04-02
JP6698220B2 (ja) 2020-05-27
TW201817443A (zh) 2018-05-16
US10159751B2 (en) 2018-12-25
HRP20240171T1 (hr) 2024-04-12
ES2966895T3 (es) 2024-04-24
CA3038705A1 (en) 2018-05-03
US11033633B2 (en) 2021-06-15
US11844766B2 (en) 2023-12-19
KR102576346B1 (ko) 2023-09-07
US20240082412A1 (en) 2024-03-14
NZ751736A (en) 2021-07-30
BR112019007803A2 (pt) 2019-09-03
TWI734853B (zh) 2021-08-01
EP3528839A1 (en) 2019-08-28
CL2019001104A1 (es) 2019-06-21
CN109996559A (zh) 2019-07-09
EP3528839B1 (en) 2023-11-08
US10525145B2 (en) 2020-01-07
RS65125B1 (sr) 2024-02-29
KR20190101954A (ko) 2019-09-02

Similar Documents

Publication Publication Date Title
MX2023004834A (es) Formulaciones de vacunas de glicoconjugados de expec.
MX2018002340A (es) Metodos y composiciones para proteccion inmunitaria contra e. coli patogena extraintestinal.
EA201691478A1 (ru) Новый полисахарид и его применения
CY1123450T1 (el) Μεθοδος καθαρισμου συζευγματων βασει il-15/il-15ra
EA201990566A1 (ru) Композиции, содержащие бактериальные штаммы
MX2019008303A (es) Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
EP4286000A3 (en) Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
AU2005332599A8 (en) Polyinosinic acid-polycytidylic acid-based adjuvant
MX2007010044A (es) Inmunogenos de escherichia coli uropatogenica.
WO2015175355A8 (en) Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates
CO2021001926A2 (es) Composiciones de escherichia coli y métodos de estas
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX2022015734A (es) Proteinas de exotoxina a modificadas.
EA201991126A1 (ru) Снижение вирулентности бактерий путем снижения транспорта фолата у бактерий
MX2023003169A (es) Composiciones de vacunas multivalentes y usos de las mismas.
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
UY36208A (es) “bacterias modificadas para vacunas mejoradas contra la brucelosis”.
MX2015011692A (es) Suspension de proteinas como un sistema opacificante de bebidas.
PL404229A1 (pl) Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
AR105793A1 (es) Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal
AR125423A1 (es) Vacunas contra infecciones del tracto urinario
AR116010A1 (es) Composiciones de escherichia coli y métodos de estas
WO2024107729A3 (en) Multivalent vaccine compositions and uses thereof
PL408955A1 (pl) Immunogenny koniugat i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez pałeczki jelitowe z rodziny Enterobacteriaceae
MX2022015860A (es) Inmunizacion bacteriana que utiliza una vacuna con nanoparticulas.